TACSTD2 and prostate carcinoma: 3.6. GSE1 and TACSTD2 Interaction or Expression Profiles Reflect Abiraterone/Enzalutamide Drug Resistance, Androgen Sensitivity, and Castration Resistance in Patients with Prostate Cancer